Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02536469 | HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00004927 | BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | completed | Phase 1 | — | R-PharmINDUSTRY | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00207129 |
| Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies |
| completed |
| Phase 1 |
| 25 |
| R-PharmINDUSTRY |
| 1 |
| Jan 30, 2017 |
| clinicaltrials |
| NCT01018966 | Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors | completed | Phase 1 | 25 | R-PharmINDUSTRY | 0 | Jan 30, 2017 | clinicaltrials |
| NCT01406119 | An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 14 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01980667 | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | completed | Phase 1 | 41 | PharmaMarINDUSTRY | 2 | Jan 26, 2017 | clinicaltrials |
| NCT01721148 | A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | completed | Phase 1 | 39 | ASLAN PharmaceuticalsOTHER | 0 | Jan 25, 2017 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01929603 | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Jan 16, 2017 | clinicaltrials |
| NCT00949949 | Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy | completed | Phase 1 | 38 | Mayo ClinicOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | completed | Phase 1 | 40 | BiogenINDUSTRY | 1 | Jan 9, 2017 | clinicaltrials |
| NCT00725933 | Administration of BIIB028 to Subjects With Solid Tumors | completed | Phase 1 | 43 | BiogenINDUSTRY | 1 | Jan 9, 2017 | clinicaltrials |
| NCT00970411 | Study of KRN951 in Patients With Solid Tumors | completed | Phase 1 | 12 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00996892 | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 178 | Genentech, Inc.INDUSTRY | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00618735 | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | completed | Phase 1 | 68 | BiogenINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT00741403 | A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | completed | Phase 1 | 39 | Cornerstone PharmaceuticalsINDUSTRY | 2 | Dec 29, 2016 | clinicaltrials |
| NCT01204450 | Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma | terminated | Phase 1 | 7 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT01976143 | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety | completed | Phase 1 | 33 | Nektar TherapeuticsINDUSTRY | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01832298 | Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor | completed | Phase 1 | 39 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Dec 20, 2016 | clinicaltrials |
| NCT01967043 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies | completed | Phase 1 | 34 | Kinex Pharmaceuticals Inc.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02977364 | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | unknown | Phase 1 | 50 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT00359671 | Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) | terminated | Phase 1 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 29, 2016 | clinicaltrials |
| NCT01611857 | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | completed | Phase 1 / Phase 2 | 49 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02353026 | Phase I Study of Intravenous Artesunate for Solid Tumors | completed | Phase 1 | 19 | Georgetown UniversityOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01773434 | A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103) | completed | Phase 1 | 46 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT00876109 | A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | completed | Phase 1 | 108 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01075464 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 64 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01106599 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 61 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01139723 | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | completed | Phase 1 | 54 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01226277 | A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 42 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01332604 | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01363024 | Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00974896 | QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | completed | Phase 1 | 46 | NantCell, Inc.INDUSTRY | 0 | Oct 27, 2016 | clinicaltrials |
| NCT01598129 | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | completed | Phase 1 | 12 | Targovax OyINDUSTRY | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 5 | Oct 13, 2016 | clinicaltrials |
| NCT00003899 | Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01538095 | Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Oct 3, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 | 47 | AbbVieINDUSTRY | 3 | Sep 27, 2016 | clinicaltrials |
| NCT00019565 | PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy | completed | Phase 1 | 53 | National Institutes of Health Clinical Center (CC)NIH | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01447225 | Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors | completed | Phase 1 | 43 | Merrimack PharmaceuticalsINDUSTRY | 2 | Sep 14, 2016 | clinicaltrials |
| NCT00734305 | Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 44 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02884128 | A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors | completed | Phase 1 | 16 | PharmaEngineINDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| NCT00467779 | Study of Cobimetinib in Participants With Solid Tumors | completed | Phase 1 | 119 | Genentech, Inc.INDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT01682135 | A Study in Participants With Advanced Solid Tumors | completed | Phase 1 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT02126527 | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 26, 2016 | clinicaltrials |
| NCT02862028 | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) | unknown | Phase 1 / Phase 2 | 20 | Shanghai International Medical CenterINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT02844881 | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The First People's Hospital of LianyungangOTHER | 1 | Aug 11, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Feb 3, 2017source: clinicaltrials